Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer

Update Il y a 4 ans
Reference: NCT00751790

Extract

Efficacy and safety of a triptorelin 6-month formulation in patients with advanced prostate cancer. It was assumed that during the study treatment >90% of the patients would achieve and maintain castrate levels of serum testosterone.


Inclusion criteria

  • Prostatic Neoplasm

Links